{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:04:35Z","timestamp":1761239075970,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.metabol.2023.155553","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T12:26:55Z","timestamp":1680697615000},"page":"155553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Commentary on the endocrine society clinical practice guideline on the \u201ctreatment of hypercalcemia of malignancy in adults\u201d"],"prefix":"10.1016","volume":"143","author":[{"given":"Ghada","family":"El-Hajj Fuleihan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"year":"2013","series-title":"Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group","author":"BJ","key":"10.1016\/j.metabol.2023.155553_bb0010"},{"issue":"4","key":"10.1016\/j.metabol.2023.155553_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.metabol.2023.155553_bb0020","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.2174\/092986711796642490","article-title":"Malignant hypercalcemia","volume":"18","author":"Basso","year":"2011","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.metabol.2023.155553_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.metabol.2023.155553_bb0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1026597816193","article-title":"Hypercalcemia of malignancy","volume":"1","author":"Grill","year":"2000","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"10.1016\/j.metabol.2023.155553_bb0035","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.metabol.2023.155553_bb0040","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.metabol.2023.155553_bb0045","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of Hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm Metab Res"},{"issue":"18","key":"10.1016\/j.metabol.2023.155553_bb0050","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","author":"Hu","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.metabol.2023.155553_bb0055","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.metabol.2023.155553_bb0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ecl.2021.08.002","article-title":"Treatment of hypercalcemia of malignancy","volume":"50","author":"Chakhtoura","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"15","key":"10.1016\/j.metabol.2023.155553_bb0065","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.metabol.2023.155553_bb0070","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/clinem\/dgac290","article-title":"Enhancing the trustworthiness of the Endocrine Society's clinical practice guidelines","volume":"107","author":"McCartney","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0075","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1210\/clinem\/dgac631","article-title":"A systematic review supporting the Endocrine Society clinical practice guideline on the treatment of hypercalcemia of malignancy in adults","volume":"108","author":"Seisa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/clinem\/dgac630","article-title":"Patient and physician decisional factors regarding hypercalcemia of malignancy treatment: a novel mixed-methods study","volume":"108","author":"Bassatne","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.metabol.2023.155553_bb0085","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.metabol.2023.155553_bb0090","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1210\/jc.2013-1814","article-title":"The Endocrine Society guidelines: when the confidence cart goes before the evidence horse","volume":"98","author":"Brito","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.metabol.2023.155553_bb0100","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.metabol.2023.155553_bb0105","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"issue":"16","key":"10.1016\/j.metabol.2023.155553_bb0110","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"European Journal of Cancer (Oxford, England : 1990)"},{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.metabol.2023.155553_bb0120","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clml.2014.07.005","article-title":"Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction","volume":"14","author":"Cicci","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.metabol.2023.155553_bb0130","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(19870501)59:9<1543::AID-CNCR2820590902>3.0.CO;2-L","article-title":"Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia","volume":"59","author":"Mudde","year":"1987","journal-title":"Cancer"},{"issue":"3\u20134","key":"10.1016\/j.metabol.2023.155553_bb0135","first-page":"129","article-title":"Non-Hodgkin's lymphoma and 1,25(OH)2D-related hypercalcaemia","volume":"37","author":"Craanen","year":"1990","journal-title":"Neth J Med"},{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0140","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/BF02114405","article-title":"1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports","volume":"9","author":"Devogelaer","year":"1990","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2023.155553_bb0150","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.metabol.2023.155553_bb0155","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2023.155553_bb0160","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155553_bb0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","article-title":"Cinacalcet hydrochloride relieves hypercalcemia in japanese patients with parathyroid cancer and intractable primary hyperparathyroidism","volume":"35","author":"Takeuchi","year":"2017","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"10.1016\/j.metabol.2023.155553_bb0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.metabol.2023.155553_bb0175","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4158\/EP14410.OR","article-title":"The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia","volume":"21","author":"Fountas","year":"2015","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcrpr.2018.01.002","article-title":"Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma","volume":"5","author":"Hsu","year":"2018","journal-title":"J Cancer Res Pract"},{"issue":"1","key":"10.1016\/j.metabol.2023.155553_bb0185","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab","volume":"171","author":"Karuppiah","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2023.155553_bb0190","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/EJE-14-0482","article-title":"Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma","volume":"171","author":"Nadarasa","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155553_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/qjmed\/hcu166","article-title":"Use of denosumab in parathyroid carcinoma with refractory hypercalcemia","volume":"108","author":"Tong","year":"2015","journal-title":"QJM"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155553_bb0205","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy","volume":"2015","author":"Von Schwartzenberg","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"10.1016\/j.metabol.2023.155553_bb0210","first-page":"e141","article-title":"Denosumab for the treatment of refractory hypercalcemia in metastatic parathyroid carcinoma","volume":"1","author":"Itoshima","year":"2015","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.metabol.2023.155553_bb0215","unstructured":"Zoledronic acid approval by FDA. n.d. Accessed November 26, 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ label\/2016\/203231s011lbl.pdf."},{"issue":"9","key":"10.1016\/j.metabol.2023.155553_bb0220","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155553_bb0225","unstructured":"Denosumab approval by FDA. n.d. Accessed November 26, 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ label\/2018\/125320s182lbl.pdf."},{"key":"10.1016\/j.metabol.2023.155553_bb0230","unstructured":"Cinacalcet approval by FDA n.d.Accessed March 8, 2023 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021688s017lbl.pdf."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:31:26Z","timestamp":1758429086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":46,"alternative-id":["S0026049523001567"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155553","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary on the endocrine society clinical practice guideline on the \u201ctreatment of hypercalcemia of malignancy in adults\u201d","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155553"}}